

Expression of CCND1 is stimulated by CT- NNB1:TCF4,LEF1 and inhibited by VENTX:TCF4,LEF1

Orlic-Milacic, M., Vegi, NM.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](https://creativecommons.org/licenses/by/4.0/). For more information see our [license](https://reactome.org/licenses/).

09/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)

Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)

Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)

Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 88


This document contains 1 reaction ([see Table of Contents](#))

Expression of CCND1 is stimulated by CTNNB1:TCF4,LEF1 and inhibited by VENTX:TCF4,LEF1 ↗

Stable identifier: R-HSA-8853956

Type: omitted

Compartments: nucleoplasm



While the complex of beta-catenin (CTNNB1) and TCF4/LEF1 transcription factors stimulates cyclin D1 (CCND1) transcription, binding of VENTX to TCF4 and/or LEF1 results in the inhibition of CCND1 transcription. VENTX is predominantly expressed in hematopoietic cells and its interaction with TCF4/LEF1 is implicated in the inhibition of cellular proliferation induced by WNT signaling (Gao et al. 2010).

Literature references

Shtutman, M., Albanese, C., D'Amico, M., Zhurinsky, J., Simcha, I., Pestell, R. et al. (1999). The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. *Proc. Natl. Acad. Sci. U.S.A.*, 96, 5522-7. ↗

McCormick, F., Tetsu, O. (1999). Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. *Nature*, 398, 422-6. ↗

Le, Y., Silberstein, L.E., Giese, RW., Gao, H., Wu, X., Zhu, Z. (2010). VentX, a novel lymphoid-enhancing factor/T-cell factor-associated transcription repressor, is a putative tumor suppressor. *Cancer Res.*, 70, 202-11. ↗

Editions

2019-06-28	Authored	Orlic-Milacic, M.
2019-10-18	Reviewed	Vegi, NM.
2019-11-01	Edited	Orlic-Milacic, M.